There are some pretty significant near term catalysts from Cardiol’s active COVID trials with the FDA, but I don’t think investors are giving enough credit to their high concentration Pharma-grade CBD product, Cortalex, that is currently selling in Canada’s largest drug store. CBD, in high concentration has proven incredibly effective for many ailments, one of them being childhood epilepsy, as referenced by Harvard University. The market for this in Canada alone is worth $100 million.
The team is led by some of the most qualified veterans in the medical world. This is not a cannabis company as many classify it - this is a groundbreaking BioTech company.
It's only closest comparable, sitting at a monstrous $4.1 billion market cap, is GW Pharma, who has had massive stock success after selling their high concentration CBD product in the U.S. for childhood epilepsy. GW however, unlike Cardiol, can not sell their product in Canada, as it is too expensive for the Government backed health care system.
One of Cardiol's biggest competitive advantages is it's proprietary process for purifying and concentrating CBD to pharmaceutical grade, through their partnership with Dalton Pharmaceuticals, an industry leader.
We're keeping an eye on this one.